Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in Hepatocellular Carcinoma (HCC)

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lee, Kyeong Ah ^a   Ahn, Ji Young ^a   Lee, Sang Hee ^a   Singh Sekhon, Simranjeet ^a   Kim, Dae Ghon ^b   Min, Jiho ^b   Kim, Yang Hoon ^a  

^a Chungbuk National University   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; APTAMER; LCN2 PROTEIN, HUMAN; LIPOCALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ONCOPROTEIN;

ADULT; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSIS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

ACUTE-PHASE PROTEINS; ADULT; AGED; APTAMERS, NUCLEOTIDE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIPOCALIN-2; LIPOCALINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTO-ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; SELEX APTAMER TECHNIQUE; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE;

EID: 84930652691     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10897     Document Type: Article

References (60)

1. Comunale, M. A., et al. Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma. Proteomics Clin Appl. 7, 690-700 (2013).
2. Zhang, Y., Fan, Y. & Mei, Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 36, e294-e299 (2012).
3. Spangenberg, H. C., Thimme, R. & Blum, H. E. Serum markers of hepatocellular carcinoma. Semin Liver Dis. 26, 385-390 (2006).
4. Gomaa, A. I., Khan, S. A., Leen, E. L., Waked, I. & Taylor-Robinson, S. D. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 15, 1301-1314 (2009).
5. Forner, A., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47, 97-104 (2008).
6. Sherman, M. Diagnosis of small hepatocellular carcinoma. Hepatology 42, 14-16 (2005).
7. Liebman, H. A., et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 310, 1427-1431 (1984).
8. Wright, L. M., Kreikemeier, J. T. & Fimmel, C. J. A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev. 31, 35-44 (2007).
9. Zinkin, N. T., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 14, 470-477 (2008).
10. Lv, Y., et al. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Eur J Surg Oncol. 39, 1129-1135 (2013).
11. He, Y. M., et al. Ultrasound-guided fine needle biopsy of intrahepatic nodules and low elevation of AFP in early diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 4, 50-54 (2005).
12. Kim, M. Y., et al. Expression profile of nine novel genes differentially expressed in hepatitis B virus-Associated hepatocellular carcinomas. Oncogene 20, 4568-75 (2001).
13. Wang, Y. P., et al. Lipocalin-2 negatively modulates the epithelial-To-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Hepatology 58, 1349-1361 (2013).
14. Hraba-Renevey, S., Turler, H., Kress, M., Salomon, C. & Weil, R. SV40-induced expression of mouse gene 24p3 involves a posttranscriptional mechanism. Oncogene 4, 601-608 (1989).
15. Kjeldsen, L., Johnsen, A. H., Sengelov, H. & Borregaard, N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 268, 10425-10432 (1993).
16. Yang, J., et al. An iron delivery pathway mediated by a lipocalin. Mol Cell. 10, 1045-1056 (2002).
17. Borkham-Kamphorst, E., et al. Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. Biochim Biophys Acta. 1832, 660-673 (2013).
18. Cesari, M., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108, 2317-2322 (2003).
19. Poon, R. T., et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 91, 1354-1360 (2004).
20. Capurro, M., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125, 89-97 (2003).
21. Dai, Z., Chen, J., Yan, F. & Ju, H. Electrochemical sensor for immunoassay of carcinoembryonic antigen based on thionine monolayer modified gold electrode. Cancer Detect Prev. 29, 233-240 (2005).
22. Gupta, D. & Lis, C. G. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 9, 69 (2010).
23. Howard, B. A., et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-Assisted laser desorption/ionization-Time of flight spectra analysis. Proteomics 3, 1720-1724 (2003).
24. Kritchevsky, S. B., Cesari, M. & Pahor, M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 66, 265-275 (2005).
25. Liu, W., et al. Evaluation of tumour-Associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol. 69, 57-63 (2009).
26. Uludag, Y. & Tothill, I. E. Cancer biomarker detection in serum samples using surface plasmon resonance and quartz crystal microbalance sensors with nanoparticle signal amplification. Anal Chem. 84, 5898-5904 (2012).
27. Ambrosi, A., Airo, F. & Merkoci, A. Enhanced gold nanoparticle based ELISA for a breast cancer biomarker. Anal Chem. 82, 1151-1156 (2010).
28. Patil, M. A., et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 24, 3737-3747 (2005).
29. Mishra, A. & Verma, M. Cancer biomarkers: are we ready for the prime time?Cancers (Basel) 2, 190-208 (2010).
30. Kim, M., et al. Arsenic removal from Vietnamese groundwater using the arsenic-binding DNA aptamer. Environ Sci Technol. 43, 9335-9340 (2009).
31. Zhu, L., et al. In vitro selection of highly efficient G-quadruplex-based DNAzymes. Anal Chem. 84, 8383-8390 (2012).
32. Ahn, J. Y., et al. Sol-gel derived nanoporous compositions for entrapping small molecules and their outlook toward aptamer screening. Anal Chem. 84, 2647-2653 (2012).
33. Carr, S. A. & Anderson, L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?Clin Chem. 54, 1749-1752 (2008).
34. Makawita, S. & Diamandis, E. P. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem. 56, 212-222 (2010).
35. Um, H. J., Kim, M., Lee, S. H. & Kim, Y. H. Preventing the formation of positive transcription elongation factor b by human cyclin T1-binding RNA aptamer for anti-HIV transcription. AIDS 26, 1599-1605 (2012).
36. Oguro, A., Ohtsu, T., Svitkin, Y. V., Sonenberg, N. & Nakamura, Y. RNA aptamers to initiation factor 4A helicase hinder capdependent translation by blocking ATP hydrolysis. RNA 9, 394-407 (2003).
37. Wang, X., Corin, K., Rich, C. & Zhang, S. Study of two G-protein coupled receptor variants of human trace amine-Associated receptor 5. Sci Rep. 1, 102 (2011).
38. Rich, R. L. & Myszka, D. G. Why you should be using more SPR biosensor technology. Drug Discov Today Technol. 1, 301-308 (2004).
39. Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510 (1990).
40. Sekhon, S. S., et al. Advances in pathogen-Associated molecules detection using Aptamer based biosensors. Mol.Cell. Toxicol. 9, 311-317 (2013).
41. Kim, L. H., Yu, H. W., Kim, Y. H., Kim, I. S. & Jang, A. Potential of Fluorophore Labeled Aptamers for Pseudomonas aeruginosa Detection in Drinking Water. J Korean SOC Appl Bioll Chem. 56, 165-171 (2013).
42. Swierczewska, M., Liu, G., Lee, S. & Chen, X. High-sensitivity nanosensors for biomarker detection. Chem Soc Rev. 41, 2641-2655 (2012).
43. Wang, J. X., et al. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma. Chin Med J. (Engl) 118, 1278-1284 (2005).
44. Trinchet, J. C., et al. [Epidemiology, prevention, screening and diagnosis of hepatocellular carcinoma]. Bull Cancer 96, 35-43 (2009).
45. Ju, J. miRNAs as biomarkers in colorectal cancer diagnosis and prognosis. Bioanalysis 2, 901-906 (2010).
46. Salagierski, M. & Schalken, J. A. PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. Cancers (Basel) 2, 1432-1440 (2010).
47. Addae, S. A., et al. Rapid and Sensitive Colorimetric ELISA using Silver Nanoparticles, Microwaves and Split Ring Resonator Structures. Nano Biomed Eng. 2, 155-164 (2010).
48. de Haas, E. C., et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10, 1041-1048 (2008).
49. Seo, S. M., et al. An ELISA-on-A-chip biosensor system coupled with immunomagnetic separation for the detection of Vibrio parahaemolyticus within a single working day. J Food Prot. 73, 1466-1473 (2010).
50. Jeong, H. H., et al. Real-Time label-free immunoassay of interferon-gamma and prostate-specific antigen using a Fiber-Optic Localized Surface Plasmon Resonance sensor. Biosens Bioelectron. 39, 346-351 (2013).
51. Chiappini, F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatology 2012, 684802 (2012).
52. Pfafflin, A. & Schleicher, E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem. 393, 1473-1480 (2009).
53. Lee, S. P., et al. Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT) after drug-eluting stent implantation for coronary heart disease: results from the CILON-T randomized trial POCT substudy. J Atheroscler Thromb. 18, 914-923 (2011).
54. Shimetani, N. [Current status of POCT and its future challenges]. Rinsho Byori. 59, 864-868 (2011).
55. Rich, R. L., Day, Y. S., Morton, T. A. & Myszka, D. G. High-resolution and high-Throughput protocols for measuring drug/human serum albumin interactions using BIACORE. Anal Biochem. 296, 197-207 (2001).
56. Riedel, T., et al. Diagnosis of Epstein-Barr virus infection in clinical serum samples by an SPR biosensor assay. Biosens Bioelectron. 55, 278-284 (2014).
57. Oh, Y. K., Joung, H. A., Han, H. S., Suk, H. J. & Kim, M. G. A three-line lateral flow assay strip for the measurement of C-reactive protein covering a broad physiological concentration range in human sera. Biosens Bioelectron. 61, 285-289 (2014).
58. Weiss, M., Dullenkopf, A. & Moehrlen, U. Evaluation of an improved blood-conserving POCT sampling system. Clin Biochem. 37, 977-984 (2004).
59. Jung, W., et al. An innovative sample-To-Answer polymer lab-on-A-chip with on-chip reservoirs for the POCT of thyroid stimulating hormone (TSH). Lab Chip. 13, 4653-62 (2013).
60. DuBois, J. A. The role of POCT and rapid testing. Here is an overview of an evolving approach to direct patient care. MLO Med Lab Obs. 45, 18, 20, 2 (2013).